These results suggested that Chek2 depletion/inhibition in tumor cells activates STING pathway and upregulates PD-L1 expression therefore, we hypothesized that Chek2 depletion/inhibition will sensitize gliomas to PD-1 or PD-L1 blockade, given that these forms of immunotherapy are thought to involve activity of effector T cells (Fig. 5i). This evidence concerns the gene CHEK2 and glioma.